A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma

✍ Scribed by Todd M. Zimmerman; David L. Grinblatt; Rebecca Malloy; Stephanie F. Williams

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 73 KB
• Volume: 83
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19981015)83:8<1540::aid-cncr8>3.0.co;2-v

✦ Synopsis

BACKGROUND.

Paclitaxel, an effective chemotherapeutic agent in the management of breast carcinoma, may have activity in women whose disease has recurred after high dose chemotherapy. With this is mind the authors explored the addition of a 120-hour continuous infusion of paclitaxel to a previously reported regimen comprised of high dose cyclophosphamide and thiotepa.

METHODS. Thirty-one women with advanced breast carcinoma (30 patients with

Stage IV disease and 1 patient with Stage IIIB disease) underwent harvest and cryopreservation of bone marrow and/or peripheral blood progenitor cells. High dose cyclophosphamide (2.5 g/m 2 ) and thiotepa (225 mg/m 2 ) were administered intravenously on Days Ϫ7, Ϫ5, and Ϫ3. Paclitaxel was administered as a 120-hour continuous infusion starting on Day Ϫ7.